...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer science. >Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy
【24h】

Apelin as a marker for monitoring the tumor vessel normalization window during antiangiogenic therapy

机译：Apelin作为在抗血管生成治疗期间监测肿瘤血管正常化窗口的标记

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Antiangiogenic agents transiently normalize tumor vessel structure and improve vessel function, thereby providing a window of opportunity for enhancing the efficacy of chemotherapy or radiotherapy. Currently, there are no reliable predictors or markers reflecting this vessel normalization window during antiangiogenic therapy. Apelin, the expression of which is regulated by hypoxia, and which has well-described roles in tumor progression, is an easily measured secreted protein. Here, we show that apelin can be used as a marker for the vessel normalization window during antiangiogenic therapy. Mice bearing s.c. tumors resulting from inoculation of the colon adenocarcinoma cell line HT29 were treated with a single injection of bevacizumab, a mAb neutralizing vascular endothelial growth factor. Tumor growth, vessel density, pericyte coverage, tumor hypoxia, and small molecule delivery were determined at four different times after treatment with bevacizumab (days 1, 3, 5, and 8). Tumor growth and vessel density were significantly reduced after bevacizumab treatment, which also significantly increased tumor vessel maturity, and improved tumor hypoxia and small molecule delivery between days 3 and 5. These effects abated by day 8, suggesting that a time window for vessel normalization was opened between days 3 and 5 during bevacizumab treatment in this model. Apelin mRNA expression and plasma apelin levels decreased transiently at day 5 post-treatment, coinciding with vessel normalization. Thus, apelin is a potential indicator of the vessel normalization window during antiangiogenic therapy.
机译：抗血管生成剂可暂时使肿瘤血管结构正常化并改善血管功能，从而为增强化学疗法或放射疗法的效力提供了机会之窗。当前，在抗血管生成治疗过程中，尚无可靠的预测因子或标志物反映该血管正常化窗口。 Apelin是一种易于测量的分泌蛋白，其表达受到缺氧的调节，并且在肿瘤进展中具有众所周知的作用。在这里，我们显示了apelin可以用作抗血管生成治疗过程中血管正常化窗口的标记。小鼠轴承s.c.用单次注射贝伐单抗（一种中和血管内皮生长因子的单克隆抗体）治疗因接种结肠腺癌细胞系HT29而产生的肿瘤。在用贝伐单抗治疗后第4天（第1、3、5和8天）确定肿瘤生长，血管密度，周细胞覆盖，肿瘤缺氧和小分子递送。贝伐单抗治疗后，肿瘤的生长和血管密度显着降低，这也显着增加了肿瘤血管的成熟度，并改善了肿瘤的缺氧和小分子在第3天到第5天之间的传递。这些影响在第8天减弱了，这表明血管正常化的时间窗口是在该模型中贝伐单抗治疗期间的第3天到第5天之间打开。治疗后第5天，Apelin mRNA表达和血浆Apelin水平瞬时下降，与血管正常化相吻合。因此，apelin是抗血管生成治疗过程中血管正常化窗口的潜在指标。

著录项

  • 来源
    《Cancer science.》 |2016年第1期|共9页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号